The market for biologic drugs in the United States is large and growing. Total US biologic sales in 2018 is estimated to have been $125 billion, an increase of 50 percent since 2014.
“Peter B. Bach, MD, a well-known critic of high drug prices, along with Jennifer A. Ohn, MPH, Preston Atteberry, MD, and Mark Trusheim, MSc, first wrote in April that biosimilar competition is an economically inefficient way to achieve the goal of lower prices; the biosimilar environment is different than the one that exists in the generic marketplace for small-molecule drugs. These authors said, instead, that biosimilars are natural monopolies and as such need price regulation in order for them to succeed and for prices to come down.”
In January 2015, CMS launched a star-rating system for U.S. dialysis facilities. This article analyzes nearly 6,000 U.S. dialysis facilities and explores trends and variations in star-rating scores based on facility characteristics and local demographic factors. Statistical tests show variation across states and by demographic factors.